MoonLake Immunotherapeutics
$ 17.80
-1.11%
09 Jun - close price
- Market Cap 1,310,354,000 USD
- Current Price $ 17.80
- High / Low $ 18.91 / 17.36
- Stock P/E N/A
- Book Value 3.52
- EPS -3.88
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.78 %
- 52 Week High 62.75
- 52 Week Low 5.95
About
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to developing groundbreaking therapies for chronic inflammatory diseases, leveraging its proprietary drug delivery technology. Currently, the company is advancing its lead candidate, a novel interleukin-17 inhibitor, through various stages of clinical trials, with the potential to transform treatment paradigms and improve patient outcomes significantly. Backed by a robust research pipeline and strategic collaborations, MoonLake is strategically positioned within the immunotherapy sector, targeting significant unmet medical needs while creating potential value for investors.
Analyst Target Price
$27.62
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-25 | 2025-11-05 | 2025-08-05 | 2025-05-12 | 2025-02-26 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-02-29 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -0.98 | -0.92 | -1.1 | -0.87 | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 | -0.12 | -0.18 | -0.23 |
| Estimated EPS | -0.9213 | -0.9792 | -0.8788 | -0.72 | -0.7355 | -0.5928 | -0.44 | -0.28 | -0.19 | -0.23 | -0.23 | -0.27 |
| Surprise | -0.0587 | 0.0592 | -0.2212 | -0.15 | 0.1055 | -0.1272 | -0.12 | -0.11 | -0.03 | 0.11 | 0.05 | 0.04 |
| Surprise Percentage | -6.3714% | 6.0458% | -25.1707% | -20.8333% | 14.344% | -21.4575% | -27.2727% | -39.2857% | -15.7895% | 47.8261% | 21.7391% | 14.8148% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLTX
2026-06-09 20:10:23
MoonLake Immunotherapeutics (NASDAQ: MLTX) shareholders approved an amendment and restatement of the company's 2022 Equity Incentive Plan, adding 5,000,000 Class A ordinary shares for stock-based awards and extending the plan's term to June 4, 2036. They also re-elected Class I director Spike Loy, ratified Baker Tilly US, LLP as independent auditor, and approved the advisory vote on executive compensation. The plan changes include removing liberal share recycling, adding a one-year minimum vesting requirement, and revising non-employee director compensation limits.
2026-05-16 07:40:09
Cormorant Asset Management, LP and Bihua Chen have reported a combined beneficial ownership of 6.25% in MoonLake Immunotherapeutics (MLTX), totaling 4,480,433 Class A ordinary shares. This disclosure, an amendment to a previous filing, indicates shared voting and dispositive power over these shares. The ownership percentage is based on 71,727,875 Class A shares outstanding as of February 1, 2026.
2026-05-13 20:38:45
MoonLake Immunotherapeutics (MLTX) Chief Financial Officer Matthias Bodenstedt sold 13,653 Class A ordinary shares in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $20.02, with individual trades ranging from $19.50 to $20.83. Following this sale, Bodenstedt directly holds 1,172,431 Class A ordinary shares, indicating the transaction was a planned liquidity event rather than an opportunistic one.
2026-04-29 09:39:13
MoonLake Immunotherapeutics (MLTX) has released a proxy filing summary detailing the agenda for their annual meeting on June 5, 2025. Key proposals include the election of three Class III directors, the ratification of Baker Tilly US, LLP as the independent auditor, and an advisory vote on executive compensation. The company's board, which is majority independent, recommends voting "FOR" all proposals.
2026-04-19 17:08:55
MoonLake Immunotherapeutics (NASDAQ: MLTX) is seeking shareholder approval to amend and restate its 2022 Equity Incentive Plan, which would add 5,000,000 Class A Ordinary Shares to the pool, resulting in a potential dilution of approximately 6.2%. The proposals will be voted on at the 2026 Annual General Meeting on June 4, 2026, and also include the election of a Class I director, ratification of their independent auditor, and an advisory vote on executive compensation. The company emphasizes using equity compensation to attract and retain talent in line with growth-stage biotech practices and long-term shareholder interests.
2026-04-17 07:40:00
Insiders at MoonLake Immunotherapeutics (MLTX) have recently sold shares, with Co-Founder Jorge da Silva netting US$2.8m and Co-Founder & Chief Scientific Officer Kristian Reich selling US$3.0m worth. While there's significant insider ownership (10% or US$140m), the sales, particularly below the current share price, might suggest insiders view the stock as fully valued, despite it not necessarily being a strong negative indicator. The article recommends careful consideration of these transactions alongside other risk factors for the company.
